GSE211248
Transcriptomics reveals the molecular transcriptional regulatory network of Xinhuitong in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome
Research purpose: To explore the key targets and core signal pathways of XHT (Xinhuitong, XHT) in regulating coronary heart disease with Qi deficiency and blood stasis syndrome through transcriptomics, and reveal the transcriptional regulatory network of XHT in treating coronary heart disease with Qi deficiency and blood stasis syndrome.  Research method: Using transcriptomics RNA-Seq technology, gene sequencing of myocardial tissues in the ischemic marginal zone of the Qi deficiency and blood stasis syndrome model group and the high-dose Yiqi Huoxue prescription group and searching for differential genes, from the perspective of gene regulation and expression patterns To study the possible effective drug targets and effect mechanism pathways of XHT in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome, and to further explore the treatment of coronary heart disease with Qi deficiency and blood by Chinese medicine compound prescriptions. The possible pharmacological mechanism of blood stasis syndrome, and the key molecular nodes and effect mechanism pathways suggested by it are verified by molecular biology methods. Overall design: Comparative gene expression profiling analysis of RNA-seq data